Charlie Bolten
Vice President @ BioGenerator
Charlie Bolten is a Series A investor at BioGenerator focused on Biotechnology and Health Care. Charlie Bolten was recruited to BioGenerator in July of 2009.Charlie participates in all aspects of technology commercialization at BioGenerator. His specific responsibilities include the BioGenerator Spark Fund and BioGenerator Accelerator Labs programs, which he conceived of and directs. Charlie serves as the Commercialization Director of theSt. Louis Regional i6 Project where he chairs the Project Core Team and leads all investment activity.Since joining BioGenerator in 2009, Charlie has led 19 investments in 15 portfolio companies, typically participating in formation of the company and/or leading the first investment syndicate. Example portfolio companies include Confluence Life Sciences, Apse, Kypha, X-tend Energy, MediBeacon, Euclises and Array Bridge. Charlie serves on the Board of Directors for various portfolio companies.At the time of his recruitment to BioGenerator, Charlie held the position of Principal Scientist and Project Leader in the Pfizer Exploratory Immunobiology group, where he led a reverse pharmacology collaboration with PTC Therapeutics focusing on post-transcriptional regulation of T cell cytokines and was the Research Project Leader for small molecule discovery program targeting an effector T cell subtype-selective receptor.
- Total investments:
- 7
- Last investment:
- Lead investor:
- 29%
Last updated:
For AI agents: llms.txt
Industries Charlie Bolten invests in
Stages Charlie Bolten invests in
Countries Charlie Bolten invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 3 (43%)
- Health Care 2 (29%)
- Farming 1 (14%)
- Consumer 1 (14%)
- Agriculture 1 (14%)
Stage
- Series A 3 (43%)
- Funding Round 2 (29%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Plastomics
|
Plastomics is a biotechnology startup that focuses in developing the next generation of crops by using chloroplast genetic engineering. Its technology platform is applicable to different crops and traits. Plastomics provides solutions for the many current industry challenges.The company was founded in 2016 and headquartered in St. Louis,Missouri. | $7.1M / Series A / Nov 16, 2021 | |
Euclises Pharmaceuticals
|
Euclises Pharmaceuticals, Inc is developing novel pain and cancer medications that offer superior safety margins compared to existing drugs. The company is based on new inventions from Dr. John Talley, the most accomplished medicinal chemist in the world. Dr. Talley previously invented Celebrex and seven other approved drugs. New compounds fromEuclises will offer both improved efficacy and safety relative to existing therapies. Euclises is located at the BioGenerator Accelerator Labs. | Sep 23, 2015 | |
|
Euclises Pharmaceuticals
|
Euclises Pharmaceuticals, Inc is developing novel pain and cancer medications that offer superior safety margins compared to existing drugs. The company is based on new inventions from Dr. John Talley, the most accomplished medicinal chemist in the world. Dr. Talley previously invented Celebrex and seven other approved drugs. New compounds fromEuclises will offer both improved efficacy and safety relative to existing therapies. Euclises is located at the BioGenerator Accelerator Labs. | Series A / Apr 07, 2015 | |
YourBevCo
|
YourBevCo, LLC is a beverage device company developing a pipeline of innovative, disruptive consumer devices that safely and effectively remove problematic ingredients from beverages that are known to cause allergic or sensitivity reactions. | Feb 19, 2015 | |
ImmunoPhotonics
|
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a strategic partnership with Veterinary Cancer Therapeutics, LLC. The company was founded in 2008 and is based in Columbia, Missouri. | Series A / Jan 26, 2015 | |
|
Euclises Pharmaceuticals
|
Euclises Pharmaceuticals, Inc is developing novel pain and cancer medications that offer superior safety margins compared to existing drugs. The company is based on new inventions from Dr. John Talley, the most accomplished medicinal chemist in the world. Dr. Talley previously invented Celebrex and seven other approved drugs. New compounds fromEuclises will offer both improved efficacy and safety relative to existing therapies. Euclises is located at the BioGenerator Accelerator Labs. | Series A / Sep 09, 2014 | |
|
ImmunoPhotonics
|
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a strategic partnership with Veterinary Cancer Therapeutics, LLC. The company was founded in 2008 and is based in Columbia, Missouri. | Series A / Sep 03, 2014 |
Co-Investors
About BioGenerator
The BioGenerator, the non-profit venture development organization of BioSTL, facilitates the formation of successful, sustainable bioscience companies in the St. Louis region. It provides start-up bioscience companies with pre-seed and seed investment funds, shared lab space with specialized equipment, and in-depth management support.
BioGenerator Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Charlie Bolten
Vice President
|
|||
Dan Broderick
Vice President
|
|||
David Christenson
Entrepreneur In Residence
|
|||
Dennis Schafer
Senior Entrepreneur in Residence
|
|||
Nandini Kishore
Entrepreneur in Residence
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Charlie Bolten invest in?
Charlie Bolten invests primarily in Biotechnology, Health Care and Farming startups, most often at Series A and Funding Round stage. Most of the 7 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Charlie Bolten?
Public channels for Charlie Bolten include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Charlie Bolten last invest?
The most recent investment recorded for Charlie Bolten closed in Nov 2021. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
